Arrowhead Pharmaceuticals, Inc. (ARWR)
USD 10.87
(-9.91%)
USD 10.87
(-9.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 478.39 Million USD | -18.36% |
| 2022 | 585.97 Million USD | 94.47% |
| 2021 | 301.32 Million USD | 396.22% |
| 2020 | 60.72 Million USD | -42.61% |
| 2019 | 105.8 Million USD | 546.4% |
| 2018 | 16.36 Million USD | -29.31% |
| 2017 | 23.15 Million USD | -30.16% |
| 2016 | 33.15 Million USD | 46.39% |
| 2015 | 22.64 Million USD | 34.55% |
| 2014 | 16.83 Million USD | 45.16% |
| 2013 | 11.59 Million USD | 50.21% |
| 2012 | 7.71 Million USD | 132.19% |
| 2011 | 3.32 Million USD | -22.26% |
| 2010 | 4.27 Million USD | 50.35% |
| 2009 | 2.84 Million USD | -42.57% |
| 2008 | 4.95 Million USD | 45.83% |
| 2007 | 3.39 Million USD | 16.3% |
| 2006 | 2.92 Million USD | 185.16% |
| 2005 | 1.02 Million USD | 48.48% |
| 2004 | 689.69 Thousand USD | 617.11% |
| 2003 | 96.17 Thousand USD | -94.04% |
| 2002 | 1.61 Million USD | 19.5% |
| 2001 | 1.35 Million USD | 13.1% |
| 2000 | 1.19 Million USD | 10.75% |
| 1999 | 1.07 Million USD | -60.24% |
| 1998 | 2.71 Million USD | 1.07% |
| 1997 | 2.68 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 459.74 Million USD | 1.58% |
| 2024 Q1 | 452.57 Million USD | -5.4% |
| 2024 Q3 | 544.78 Million USD | 18.5% |
| 2023 Q2 | 426.2 Million USD | -13.92% |
| 2023 FY | 478.39 Million USD | -18.36% |
| 2023 Q1 | 495.11 Million USD | -15.51% |
| 2023 Q3 | 413.87 Million USD | -2.89% |
| 2023 Q4 | 478.39 Million USD | 15.59% |
| 2022 Q1 | 265.97 Million USD | -11.73% |
| 2022 Q2 | 251.3 Million USD | -5.52% |
| 2022 Q3 | 277.6 Million USD | 10.46% |
| 2022 FY | 585.97 Million USD | 94.47% |
| 2022 Q4 | 585.97 Million USD | 111.08% |
| 2021 Q3 | 298.03 Million USD | -4.24% |
| 2021 Q4 | 301.32 Million USD | 1.1% |
| 2021 FY | 301.32 Million USD | 396.22% |
| 2021 Q1 | 44.77 Million USD | -26.26% |
| 2021 Q2 | 311.24 Million USD | 595.07% |
| 2020 Q2 | 67.51 Million USD | -23.35% |
| 2020 Q3 | 63.14 Million USD | -6.47% |
| 2020 FY | 60.72 Million USD | -42.61% |
| 2020 Q4 | 60.72 Million USD | -3.83% |
| 2020 Q1 | 88.07 Million USD | -16.76% |
| 2019 Q2 | 133.3 Million USD | -21.33% |
| 2019 Q3 | 111.15 Million USD | -16.61% |
| 2019 FY | 105.8 Million USD | 546.4% |
| 2019 Q4 | 105.8 Million USD | -4.81% |
| 2019 Q1 | 169.44 Million USD | 935.18% |
| 2018 Q3 | 11.14 Million USD | -16.11% |
| 2018 Q2 | 13.28 Million USD | -26.29% |
| 2018 Q1 | 18.02 Million USD | -22.17% |
| 2018 FY | 16.36 Million USD | -29.31% |
| 2018 Q4 | 16.36 Million USD | 46.89% |
| 2017 Q2 | 33.53 Million USD | -28.72% |
| 2017 Q4 | 23.15 Million USD | -9.34% |
| 2017 FY | 23.15 Million USD | -30.16% |
| 2017 Q1 | 47.04 Million USD | 41.92% |
| 2017 Q3 | 25.53 Million USD | -23.84% |
| 2016 Q2 | 20.68 Million USD | 8.78% |
| 2016 FY | 33.15 Million USD | 46.39% |
| 2016 Q3 | 26.1 Million USD | 26.24% |
| 2016 Q4 | 33.15 Million USD | 26.98% |
| 2016 Q1 | 19.01 Million USD | -16.04% |
| 2015 FY | 22.64 Million USD | 34.55% |
| 2015 Q1 | 16.42 Million USD | -2.4% |
| 2015 Q2 | 18.18 Million USD | 10.68% |
| 2015 Q3 | 14.44 Million USD | -20.55% |
| 2015 Q4 | 22.64 Million USD | 56.77% |
| 2014 Q3 | 10.81 Million USD | -17.47% |
| 2014 FY | 16.83 Million USD | 45.16% |
| 2014 Q1 | 11.78 Million USD | 1.62% |
| 2014 Q2 | 13.1 Million USD | 11.22% |
| 2014 Q4 | 16.83 Million USD | 55.63% |
| 2013 Q3 | 8.18 Million USD | -5.5% |
| 2013 Q4 | 11.59 Million USD | 41.7% |
| 2013 Q1 | 7.62 Million USD | -1.2% |
| 2013 FY | 11.59 Million USD | 50.21% |
| 2013 Q2 | 8.65 Million USD | 13.53% |
| 2012 Q2 | 8.51 Million USD | 16.42% |
| 2012 FY | 7.71 Million USD | 132.19% |
| 2012 Q1 | 7.31 Million USD | 119.99% |
| 2012 Q3 | 8.03 Million USD | -5.58% |
| 2012 Q4 | 7.71 Million USD | -3.99% |
| 2011 Q4 | 3.32 Million USD | 22.19% |
| 2011 Q1 | 7.9 Million USD | 84.79% |
| 2011 FY | 3.32 Million USD | -22.26% |
| 2011 Q3 | 2.72 Million USD | -9.75% |
| 2011 Q2 | 3.01 Million USD | -61.85% |
| 2010 Q1 | 2.57 Million USD | -9.3% |
| 2010 FY | 4.27 Million USD | 50.35% |
| 2010 Q4 | 4.27 Million USD | -16.81% |
| 2010 Q3 | 5.14 Million USD | 125.49% |
| 2010 Q2 | 2.27 Million USD | -11.63% |
| 2009 Q1 | 10.39 Million USD | 109.78% |
| 2009 Q4 | 2.84 Million USD | -36.58% |
| 2009 Q3 | 4.48 Million USD | -54.06% |
| 2009 FY | 2.84 Million USD | -42.57% |
| 2009 Q2 | 9.76 Million USD | -6.05% |
| 2008 Q4 | 4.95 Million USD | 62.1% |
| 2008 Q2 | 2.79 Million USD | 0.36% |
| 2008 Q3 | 3.05 Million USD | 9.38% |
| 2008 FY | 4.95 Million USD | 45.83% |
| 2008 Q1 | 2.78 Million USD | -18.05% |
| 2007 Q1 | 1.01 Million USD | -65.23% |
| 2007 Q3 | 2.94 Million USD | 156.51% |
| 2007 Q4 | 3.39 Million USD | 15.52% |
| 2007 FY | 3.39 Million USD | 16.3% |
| 2007 Q2 | 1.14 Million USD | 12.9% |
| 2006 Q2 | 2.58 Million USD | 77.77% |
| 2006 Q4 | 2.92 Million USD | 68.93% |
| 2006 FY | 2.92 Million USD | 185.16% |
| 2006 Q1 | 1.45 Million USD | 42.23% |
| 2006 Q3 | 1.72 Million USD | -33.24% |
| 2005 Q4 | 1.02 Million USD | 3.16% |
| 2005 FY | 1.02 Million USD | 48.48% |
| 2005 Q3 | 992.71 Thousand USD | 71.39% |
| 2005 Q1 | 351.93 Thousand USD | -48.97% |
| 2005 Q2 | 579.22 Thousand USD | 64.58% |
| 2004 Q4 | 689.69 Thousand USD | 84.92% |
| 2004 Q3 | 372.96 Thousand USD | 870.9% |
| 2004 FY | 689.69 Thousand USD | 617.11% |
| 2004 Q1 | 20.33 Thousand USD | -78.86% |
| 2004 Q2 | 38.41 Thousand USD | 88.94% |
| 2003 FY | 96.17 Thousand USD | -94.04% |
| 2003 Q1 | 1.64 Million USD | 1.81% |
| 2003 Q2 | 1.74 Million USD | 6.1% |
| 2003 Q3 | 1.8 Million USD | 3.23% |
| 2003 Q4 | 96.17 Thousand USD | -94.66% |
| 2002 Q4 | 1.61 Million USD | 2.75% |
| 2002 FY | 1.61 Million USD | 19.5% |
| 2002 Q3 | 1.57 Million USD | 10.02% |
| 2002 Q2 | 1.42 Million USD | 0.82% |
| 2002 Q1 | 1.41 Million USD | 4.85% |
| 2001 Q1 | 1.22 Million USD | 2.25% |
| 2001 FY | 1.35 Million USD | 13.1% |
| 2001 Q3 | 1.3 Million USD | 2.55% |
| 2001 Q4 | 1.35 Million USD | 3.79% |
| 2001 Q2 | 1.26 Million USD | 3.93% |
| 2000 Q4 | 1.19 Million USD | -2.95% |
| 2000 Q1 | 1.12 Million USD | 2.22% |
| 2000 Q2 | 1.17 Million USD | 4.58% |
| 2000 FY | 1.19 Million USD | 10.75% |
| 2000 Q3 | 1.23 Million USD | 4.66% |
| 1999 FY | 1.07 Million USD | -60.24% |
| 1999 Q4 | 1.1 Million USD | 10.0% |
| 1999 Q2 | 2.7 Million USD | 0.0% |
| 1999 Q3 | 1 Million USD | -62.96% |
| 1998 Q3 | 2.7 Million USD | 0.0% |
| 1998 Q2 | 2.7 Million USD | 0.0% |
| 1998 FY | 2.71 Million USD | 1.07% |
| 1998 Q4 | 2.9 Million USD | 7.41% |
| 1997 FY | 2.68 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | -42.473% |
| Alkermes plc | 933.53 Million USD | 48.755% |
| Agenus Inc. | 462.29 Million USD | -3.482% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 88.189% |
| Aptorum Group Limited | 5.25 Million USD | -9000.511% |
| Ardelyx, Inc. | 130.76 Million USD | -265.845% |
| Bicycle Therapeutics plc | 224.41 Million USD | -113.175% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -267.399% |
| ChromaDex Corporation | 26.5 Million USD | -1704.7% |
| Chimerix, Inc. | 19.74 Million USD | -2322.841% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1259.947% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -559.239% |
| CRISPR Therapeutics AG | 346.76 Million USD | -37.957% |
| Precision BioSciences, Inc. | 140.92 Million USD | -239.476% |
| Dyadic International, Inc. | 2.34 Million USD | -20338.331% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -2841.585% |
| Fortress Biotech, Inc. | 165.93 Million USD | -188.293% |
| Lantern Pharma Inc. | 2.73 Million USD | -17361.516% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -569.264% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -13457.021% |
| Incyte Corporation | 1.59 Billion USD | 69.955% |
| IO Biotech, Inc. | 17.55 Million USD | -2624.937% |
| Jaguar Health, Inc. | 45.86 Million USD | -943.017% |
| Novavax, Inc. | 2.57 Billion USD | 81.402% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -1226.724% |
| Opthea Limited | 264.6 Million USD | -80.797% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -266.002% |
| ContextLogic Inc. | 206 Million USD | -132.228% |
| MiMedx Group, Inc. | 96.33 Million USD | -396.616% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -896.189% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -13456.399% |
| NextCure, Inc. | 14.99 Million USD | -3089.905% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -11735.477% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -7064.745% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -923.535% |
| Vaxcyte, Inc. | 167.44 Million USD | -185.693% |
| PDS Biotechnology Corporation | 33.25 Million USD | -1338.372% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -103.385% |
| Pharming Group N.V. | 244.07 Million USD | -96.003% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -3912.666% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -274.353% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -7140.348% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -7140.348% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -480.338% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -7101.415% |
| Acelyrin, Inc. | 86.35 Million USD | -453.993% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -36720.728% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -3227.005% |
| Summit Therapeutics Inc. | 125.25 Million USD | -281.927% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -4946.84% |
| Senti Biosciences, Inc. | 52.57 Million USD | -809.988% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -595.567% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -215.744% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -24357.566% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -35719.324% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -110.901% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -5007.185% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -110.332% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 3.26% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -4283.269% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -1638.904% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -3852.102% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 1.687% |
| Immix Biopharma, Inc. | 3.72 Million USD | -12753.785% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -1165.18% |
| MEI Pharma, Inc. | 8.35 Million USD | -5625.793% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1548.768% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -37.635% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -227.959% |
| Fortress Biotech, Inc. | 165.93 Million USD | -188.293% |
| Precigen, Inc. | 41.64 Million USD | -1048.761% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -858.121% |
| AlloVir, Inc. | 45.01 Million USD | -962.735% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -267.041% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -247.163% |
| ImmuCell Corporation | 18.81 Million USD | -2442.596% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -1594.856% |
| Onconetix, Inc. | 23.18 Million USD | -1963.726% |
| PureTech Health plc | 125.58 Million USD | -280.935% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -5245.14% |
| Elevation Oncology, Inc. | 34.28 Million USD | -1295.455% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -19466.053% |
| Seer, Inc. | 39.36 Million USD | -1115.267% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -673.668% |
| Innoviva, Inc. | 568.55 Million USD | 15.858% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -1656.978% |
| ESSA Pharma Inc. | 3.49 Million USD | -13587.562% |
| GlycoMimetics, Inc. | 6.9 Million USD | -6831.105% |
| GT Biopharma, Inc. | 6.63 Million USD | -7112.272% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -80.941% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -75.693% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -469.336% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -4794.516% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -1660.794% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -14730.244% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -548.515% |
| Aptose Biosciences Inc. | 15.8 Million USD | -2926.118% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -4233.366% |
| Soligenix, Inc. | 7.27 Million USD | -6475.894% |
| Century Therapeutics, Inc. | 175.94 Million USD | -171.904% |
| Kura Oncology, Inc. | 51.66 Million USD | -826.0% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -294.444% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -11474.885% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -7133.149% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -89.388% |
| Autolus Therapeutics plc | 263.9 Million USD | -81.272% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -4463.919% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -438.358% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -920.043% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -35.577% |
| GRI Bio, Inc. | 2.69 Million USD | -17637.857% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -58990.769% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -1438.677% |
| IGM Biosciences, Inc. | 220.17 Million USD | -117.275% |
| INmune Bio, Inc. | 18.86 Million USD | -2436.263% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -86.522% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1695.636% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -17498.181% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -14483.878% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -718.39% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -397.499% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -80.705% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 41.874% |
| Verastem, Inc. | 71.18 Million USD | -572.038% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -872.812% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -1140.059% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -877.663% |
| Histogen Inc. | 5.69 Million USD | -8297.227% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -10808.187% |
| Surrozen, Inc. | 8.14 Million USD | -5773.419% |
| Organovo Holdings, Inc. | 2.74 Million USD | -17308.661% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -152322.433% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -750.775% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -2797.226% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -836.129% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -57755.178% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -277.502% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -4323.97% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -217.048% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -18247.783% |
| Apollomics, Inc. | 14.15 Million USD | -3280.131% |
| Amarin Corporation plc | 279.58 Million USD | -71.106% |
| Mesoblast Limited | 188.79 Million USD | -153.387% |
| Turnstone Biologics Corp. | 14.14 Million USD | -3281.326% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -164.614% |
| Synaptogenix, Inc. | 5.52 Million USD | -8551.644% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -7095.999% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -181.227% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -5490.501% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -27121.572% |
| Exelixis, Inc. | 678.44 Million USD | 29.487% |
| Better Therapeutics, Inc. | 23.84 Million USD | -1906.501% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -191.619% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 19.491% |
| NLS Pharmaceutics AG | 10.68 Million USD | -4379.222% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -29364.479% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -1128.941% |
| Gritstone bio, Inc. | 125.91 Million USD | -279.919% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -3159.676% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -9301.161% |
| Avid Bioservices, Inc. | 275.66 Million USD | -73.538% |
| Insmed Incorporated | 1.66 Billion USD | 71.212% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -6117.683% |
| MediWound Ltd. | 27.18 Million USD | -1659.628% |
| OmniAb, Inc. | 87.4 Million USD | -447.357% |
| Alector, Inc. | 487.66 Million USD | 1.903% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -18.573% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -2496.418% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -1146.684% |
| Zai Lab Limited | 240.17 Million USD | -99.182% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 24.072% |
| Aura Biosciences, Inc. | 29.22 Million USD | -1536.808% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -403.161% |
| Immunic, Inc. | 25.36 Million USD | -1785.801% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -590.956% |
| Veracyte, Inc. | 93.71 Million USD | -410.451% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -18182.376% |
| FibroGen, Inc. | 585.72 Million USD | 18.326% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -2652.057% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -73151.811% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -8358.908% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 93.752% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -5735.448% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -469.363% |
| TG Therapeutics, Inc. | 169.08 Million USD | -182.929% |
| Galecto, Inc. | 5.89 Million USD | -8013.806% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -5674.867% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 81.73% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -1559.808% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -3690.429% |
| XBiotech Inc. | 8.39 Million USD | -5597.154% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -3159.676% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -799.568% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -31.749% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -1679.46% |
| Theravance Biopharma, Inc. | 169 Million USD | -183.064% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 60.646% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 4.403% |
| Vaxxinity, Inc. | 30.94 Million USD | -1445.986% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 50.808% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -7832.043% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 35.807% |
| NexImmune, Inc. | 5.08 Million USD | -9309.287% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -128709.297% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -15458.167% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 93.269% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -9181.863% |
| Scopus BioPharma Inc. | 7.45 Million USD | -6317.523% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -1719.388% |
| Ainos, Inc. | 7.39 Million USD | -6369.781% |
| Pluri Inc. | 34.11 Million USD | -1302.41% |
| Prothena Corporation plc | 135.01 Million USD | -254.318% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -96.785% |
| Celularity Inc. | 102.92 Million USD | -364.777% |
| Rallybio Corporation | 9.43 Million USD | -4969.839% |
| Cue Biopharma, Inc. | 24.44 Million USD | -1857.006% |
| MeiraGTx Holdings plc | 319.99 Million USD | -49.501% |
| Omeros Corporation | 403.25 Million USD | -18.633% |
| Humacyte, Inc. | 114.67 Million USD | -317.163% |
| Immunocore Holdings plc | 228.15 Million USD | -109.675% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -9713.128% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -523.391% |
| Blueprint Medicines Corporation | 918.64 Million USD | 47.924% |
| CalciMedica, Inc. | 4.02 Million USD | -11776.614% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -2641.176% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -210.355% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -457.454% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -72.211% |
| Pulmatrix, Inc. | 15.96 Million USD | -2896.868% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -2932.968% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -1844.201% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -90.74% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -841.972% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 60.485% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -1405.176% |
| Nutriband Inc. | 1.07 Million USD | -44239.751% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -4399.107% |
| Vor Biopharma Inc. | 59.1 Million USD | -709.404% |
| Roivant Sciences Ltd. | 773.95 Million USD | 38.189% |
| Evogene Ltd. | 17.99 Million USD | -2559.2% |
| ProKidney Corp. | 29.21 Million USD | -1537.425% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -564.624% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -67758.374% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 74.674% |
| CorMedix Inc. | 11.91 Million USD | -3914.171% |
| BioLineRx Ltd. | 50.7 Million USD | -843.533% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -220.081% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -440.914% |
| Atai Life Sciences N.V. | 49.16 Million USD | -873.089% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -1435.649% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -2563.345% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -283.83% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -8361.089% |
| MediciNova, Inc. | 3.89 Million USD | -12193.036% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -2517.156% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -31702.75% |
| GeoVax Labs, Inc. | 3.51 Million USD | -13491.084% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -20.423% |
| Biomea Fusion, Inc. | 30.69 Million USD | -1458.781% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 82.423% |
| Mereo BioPharma Group plc | 15.96 Million USD | -2897.056% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -1433.252% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -715.197% |
| Absci Corporation | 58.3 Million USD | -720.51% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -2411.497% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -1392.078% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -548.313% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -446.838% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -1316.612% |
| Allakos Inc. | 74.79 Million USD | -539.619% |
| Imunon, Inc. | 8.53 Million USD | -5508.043% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -2026.083% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -316.672% |
| BioAtla, Inc. | 48.98 Million USD | -876.585% |
| NLS Pharmaceutics AG | 10.68 Million USD | -4379.222% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -17114.466% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -266.29% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -3265.389% |
| XOMA Corporation | 145.58 Million USD | -228.61% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -1321.031% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -595.749% |
| aTyr Pharma, Inc. | 31.59 Million USD | -1414.036% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -673.806% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -963.916% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -888.368% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -16568.641% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -5764.047% |
| Akari Therapeutics, Plc | 4.58 Million USD | -10336.082% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -2597.719% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 70.997% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -118340.338% |
| UroGen Pharma Ltd. | 243.52 Million USD | -96.446% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -48.991% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -17223.192% |
| Orgenesis Inc. | 35.53 Million USD | -1246.25% |
| Entera Bio Ltd. | 1.37 Million USD | -34591.08% |
| GH Research PLC | 6.7 Million USD | -7039.084% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -6935.147% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -2441.113% |
| Xencor, Inc. | 283.55 Million USD | -68.709% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -15922.842% |
| Replimune Group, Inc. | 113.21 Million USD | -322.554% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -12632.874% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -362.079% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -118340.338% |
| Portage Biotech Inc. | 4.45 Million USD | -10650.337% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -31702.75% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1975.445% |
| OncoCyte Corporation | 49.29 Million USD | -870.404% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -11464.239% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -59887.41% |
| Purple Biotech Ltd. | 10 Million USD | -4681.509% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -8168.061% |
| scPharmaceuticals Inc. | 57.26 Million USD | -735.455% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -3761.714% |
| HilleVax, Inc. | 78.9 Million USD | -506.255% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -9373.069% |
| Tharimmune, Inc. | 1.81 Million USD | -26256.908% |
| Genprex, Inc. | 3.25 Million USD | -14600.658% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -1664.04% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -9036.555% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -232128.155% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -133324.256% |
| OKYO Pharma Limited | 7.42 Million USD | -6346.57% |
| Savara Inc. | 37.19 Million USD | -1186.271% |
| Curis, Inc. | 57.61 Million USD | -730.365% |
| Daré Bioscience, Inc. | 26.32 Million USD | -1716.911% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -1120.389% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -33029.501% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -2197.853% |
| BeiGene, Ltd. | 2.23 Billion USD | 78.583% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -2147.038% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -82.315% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -2148.707% |
| Erasca, Inc. | 78.61 Million USD | -508.554% |
| bluebird bio, Inc. | 424.62 Million USD | -12.662% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -72908.552% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 74.689% |
| DBV Technologies S.A. | 42.8 Million USD | -1017.734% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -72908.552% |
| Moderna, Inc. | 4.57 Billion USD | 89.537% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -6739.028% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -28788.285% |
| Molecular Templates, Inc. | 31.17 Million USD | -1434.728% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -2702.519% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 18.655% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -284.234% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -1643.594% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -1212.239% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -759.872% |
| MacroGenics, Inc. | 154.2 Million USD | -210.226% |
| RenovoRx, Inc. | 4.46 Million USD | -10611.823% |
| Adicet Bio, Inc. | 37.12 Million USD | -1188.766% |
| Prime Medicine, Inc. | 60.78 Million USD | -687.085% |
| Aditxt, Inc. | 28.53 Million USD | -1576.705% |
| Adagene Inc. | 45.16 Million USD | -959.103% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -264641.202% |
| Quantum-Si incorporated | 26.63 Million USD | -1696.365% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 31.42% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -15623.903% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -316.132% |
| SciSparc Ltd. | 1.59 Million USD | -29893.103% |
| Vericel Corporation | 127.7 Million USD | -274.606% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -8496.57% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -460.451% |
| Generation Bio Co. | 171.63 Million USD | -178.733% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -4041.905% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -1043.626% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -89.313% |
| Invivyd, Inc. | 51.71 Million USD | -825.087% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -420.119% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -7253.905% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -533.663% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -46755.044% |
| 2seventy bio, Inc. | 310.12 Million USD | -54.257% |
| ADMA Biologics, Inc. | 193.97 Million USD | -146.623% |
| Clene Inc. | 38.95 Million USD | -1128.184% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -1223.975% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -86.161% |
| GeoVax Labs, Inc. | 3.51 Million USD | -13491.084% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -151.436% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -3827.777% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -141.219% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -3822.902% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -894.346% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -805.339% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -29.346% |
| Evaxion Biotech A/S | 17.61 Million USD | -2615.428% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -197.268% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -212.294% |
| Trevena, Inc. | 48.26 Million USD | -891.235% |
| Surrozen, Inc. | 8.14 Million USD | -5773.419% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -2115.281% |
| Cingulate Inc. | 10.36 Million USD | -4517.279% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -17296.0% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1182.822% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -13238.557% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -3537.947% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -50.816% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -1825.188% |
| Clearmind Medicine Inc. | 3.61 Million USD | -13151.771% |
| Kronos Bio, Inc. | 54.2 Million USD | -782.622% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -916.921% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -2001.914% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2283.489% |
| Statera Biopharma, Inc. | 22.67 Million USD | -2009.633% |
| ImmunityBio, Inc. | 1.09 Billion USD | 56.127% |
| Korro Bio, Inc. | 51.75 Million USD | -824.389% |
| Kineta, Inc. | 7.22 Million USD | -6524.065% |
| BioVie Inc. | 9.7 Million USD | -4830.773% |
| Codexis, Inc. | 49.94 Million USD | -857.814% |
| Celularity Inc. | 102.92 Million USD | -364.777% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -397.044% |
| Celcuity Inc. | 51.45 Million USD | -829.814% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -138485.839% |
| Cibus, Inc. | 206.11 Million USD | -132.096% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -1026.286% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -1716.28% |
| IN8bio, Inc. | 8.77 Million USD | -5353.602% |
| Kodiak Sciences Inc. | 213.59 Million USD | -123.975% |
| Annexon, Inc. | 47.11 Million USD | -915.302% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -434.269% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -396.399% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -3394.704% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 81.624% |
| Eyenovia, Inc. | 19.78 Million USD | -2318.52% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -170.146% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -6128.225% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -1885.103% |
| Arcellx, Inc. | 339.75 Million USD | -40.806% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -3920.76% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -94.832% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -4902.51% |
| Moolec Science SA | 13.94 Million USD | -3330.461% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -1008.616% |
| Geron Corporation | 146.12 Million USD | -227.38% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -846.707% |
| Royalty Pharma plc | 6.29 Billion USD | 92.404% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -1102.71% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -162393.292% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -19344.519% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -152.908% |
| Humacyte, Inc. | 114.67 Million USD | -317.163% |
| Structure Therapeutics Inc. | 29.05 Million USD | -1546.724% |
| 89bio, Inc. | 59.96 Million USD | -697.809% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -1707.769% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -39899.164% |
| Genelux Corporation | 8.42 Million USD | -5581.591% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -6877.684% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -250.934% |
| Notable Labs, Ltd. | 4.42 Million USD | -10706.189% |
| Liquidia Corporation | 73.13 Million USD | -554.092% |
| Mustang Bio, Inc. | 17.61 Million USD | -2615.194% |
| Immunovant, Inc. | 48.95 Million USD | -877.204% |
| Quantum-Si incorporated | 26.63 Million USD | -1696.365% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -1146.359% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -15317.016% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -547.69% |
| Acasti Pharma Inc. | 11.55 Million USD | -4039.396% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -2016.046% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -17498.181% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -1197.258% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -35002.382% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -7747.605% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -1826.273% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1963.449% |
| PepGen Inc. | 34.63 Million USD | -1281.392% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -3839.312% |
| United Therapeutics Corporation | 1.18 Billion USD | 59.534% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -6749.8% |
| Solid Biosciences Inc. | 38.45 Million USD | -1143.928% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -5490.501% |
| Immuneering Corporation | 12 Million USD | -3883.81% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -152322.433% |
| Silo Pharma, Inc. | 1.56 Million USD | -30384.875% |
| Belite Bio, Inc | 4.21 Million USD | -11260.484% |
| XOMA Corporation | 145.58 Million USD | -228.61% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -19603.048% |
| Bionomics Limited | 10.15 Million USD | -4609.156% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -2126.002% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1987.854% |
| uniQure N.V. | 624.01 Million USD | 23.337% |
| Cassava Sciences, Inc. | 14.19 Million USD | -3270.13% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -264641.202% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -181.102% |
| Forte Biosciences, Inc. | 3.66 Million USD | -12949.373% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -183484.501% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -6990.411% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -6128.225% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -2652.057% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -4426.779% |
| Altimmune, Inc. | 16.54 Million USD | -2792.147% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 22.554% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1987.854% |
| Compugen Ltd. | 55.77 Million USD | -757.714% |
| Peak Bio, Inc. | 20.75 Million USD | -2205.12% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -333.077% |
| Benitec Biopharma Inc. | 4.96 Million USD | -9541.072% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -203.08% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -536.377% |
| Zura Bio Limited | 21.29 Million USD | -2146.806% |
| PolyPid Ltd. | 17.46 Million USD | -2638.665% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -325.618% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -536.377% |
| Instil Bio, Inc. | 99.8 Million USD | -379.344% |
| argenx SE | 444.95 Million USD | -7.515% |
| Immunome, Inc. | 28.65 Million USD | -1569.307% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -5638.155% |
| Verona Pharma plc | 58.84 Million USD | -713.022% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -3205.396% |
| Shattuck Labs, Inc. | 14.85 Million USD | -3119.53% |
| CervoMed Inc. | 2.59 Million USD | -18329.762% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -9715.142% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -3656.203% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -4440.959% |
| Moolec Science SA | 13.94 Million USD | -3330.461% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -20313.449% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -760.487% |
| AnaptysBio, Inc. | 364.28 Million USD | -31.323% |
| Design Therapeutics, Inc. | 11.95 Million USD | -3901.255% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -3671.602% |
| NeurAxis, Inc. | 1.91 Million USD | -24910.731% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -1128.91% |
| Lumos Pharma, Inc. | 13.33 Million USD | -3488.015% |
| Achilles Therapeutics plc | 19.08 Million USD | -2406.366% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -3205.396% |
| 180 Life Sciences Corp. | 5.38 Million USD | -8780.108% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -1928.108% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -2001.914% |
| Nutriband Inc. | 1.07 Million USD | -44239.751% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -1463.468% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -3196.74% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -19.218% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -1373.193% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -3566.078% |
| Palisade Bio, Inc. | 2.73 Million USD | -17365.863% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -9006.986% |
| Beam Therapeutics Inc. | 478.38 Million USD | -0.001% |
| Neurogene Inc. | 36.54 Million USD | -1208.9% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -20.213% |
| AEON Biopharma, Inc. | 159.88 Million USD | -199.201% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -903.966% |
| Sesen Bio, Inc. | 30.98 Million USD | -1443.99% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -1742.726% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -6192.77% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -144.403% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -149.088% |
| Athira Pharma, Inc. | 30.05 Million USD | -1491.609% |
| Vaccinex, Inc. | 5.94 Million USD | -7950.993% |
| HCW Biologics Inc. | 15.05 Million USD | -3078.261% |
| XOMA Corporation | 145.58 Million USD | -228.61% |
| Nektar Therapeutics | 267.04 Million USD | -79.141% |
| Arvinas, Inc. | 644.6 Million USD | 25.785% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -2597.719% |
| Merus N.V. | 102.15 Million USD | -368.317% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -226.881% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -402.933% |
| Rezolute, Inc. | 11.73 Million USD | -3976.956% |
| Clene Inc. | 38.95 Million USD | -1128.184% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -16701.059% |
| BeyondSpring Inc. | 48.26 Million USD | -891.092% |
| Synlogic, Inc. | 32.89 Million USD | -1354.294% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -3173.729% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -29177.234% |
| Peak Bio, Inc. | 20.75 Million USD | -2205.12% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -653.857% |
| Krystal Biotech, Inc. | 39.71 Million USD | -1104.588% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -27.014% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -380.461% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -110452.636% |
| MannKind Corporation | 721.36 Million USD | 33.683% |
| Ikena Oncology, Inc. | 22.33 Million USD | -2041.885% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -22833.365% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -366.313% |
| Gossamer Bio, Inc. | 249.14 Million USD | -92.011% |
| CohBar, Inc. | 1.03 Million USD | -46182.161% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -4375.536% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -2411.497% |
| Legend Biotech Corporation | 589.93 Million USD | 18.908% |
| Mural Oncology plc | 37.92 Million USD | -1161.311% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -260.679% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -20741.865% |
| Disc Medicine, Inc. | 22.87 Million USD | -1991.322% |
| Champions Oncology, Inc. | 28.03 Million USD | -1606.403% |
| REGENXBIO Inc. | 262.22 Million USD | -82.433% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -14140.544% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -3716.738% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -3461.668% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -2156.025% |
| Vaxart, Inc. | 34.02 Million USD | -1305.996% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -2246.284% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -1576.686% |
| Cellectis S.A. | 249.57 Million USD | -91.682% |
| Longeveron Inc. | 5.33 Million USD | -8863.65% |
| Repare Therapeutics Inc. | 41.81 Million USD | -1043.954% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 80.111% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -692.456% |
| Revolution Medicines, Inc. | 262.39 Million USD | -82.315% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -22604.794% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -5445.908% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -3953.809% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -3306.608% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -22140.353% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 90.711% |
| Denali Therapeutics Inc. | 122.96 Million USD | -289.052% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -8496.57% |
| Veru Inc. | 32.81 Million USD | -1357.941% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -6864.478% |
| Cingulate Inc. | 10.36 Million USD | -4517.279% |
| Passage Bio, Inc. | 39.26 Million USD | -1118.456% |
| Context Therapeutics Inc. | 4.19 Million USD | -11312.751% |
| Exicure, Inc. | 8.54 Million USD | -5495.859% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -1521.221% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -4462.178% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -2070.455% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -193.516% |
| Nuvalent, Inc. | 31.82 Million USD | -1403.284% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -7419.932% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -659.084% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -2557.722% |
| OmniAb, Inc. | 87.4 Million USD | -447.357% |
| Anew Medical, Inc. | 8.24 Million USD | -5704.437% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -1149.416% |
| Lipocine Inc. | 2.63 Million USD | -18078.474% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -1720.912% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -1089.67% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -1695.636% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -455.273% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -8757.434% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -478.136% |
| Ocugen, Inc. | 23.98 Million USD | -1894.705% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -930.857% |
| Q32 Bio Inc. | 233.12 Million USD | -105.205% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -5176.748% |
| Alumis Inc. Common Stock | 53.5 Million USD | -794.153% |
| Equillium, Inc. | 27.95 Million USD | -1611.164% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -131.563% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -8402.194% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -7700.302% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -204.076% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -588.995% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -4696.274% |
| Dominari Holdings Inc. | 4.63 Million USD | -10221.251% |
| Edesa Biotech, Inc. | 1.84 Million USD | -25876.346% |
| vTv Therapeutics Inc. | 29.56 Million USD | -1517.986% |
| Bio-Techne Corporation | 744.34 Million USD | 35.73% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -279.377% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -38.883% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -1079.026% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -1552.07% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -417.962% |
| Nkarta, Inc. | 105.6 Million USD | -353.021% |
| BioCardia, Inc. | 4.59 Million USD | -10322.44% |
| Iterum Therapeutics plc | 32.66 Million USD | -1364.668% |